A multicenter, national, open-label, prospective, randomized study to evaluate efficacy and tolerability of enteric-coated mycophenolate sodium 1440 mg/day with tacrolimus reduced dose versus enteric-coated mycophenolate sodium 720 mg/day with tacrolimus standard dose, in maintenance, stable, adult, kidney transplant recipients.

Trial Profile

A multicenter, national, open-label, prospective, randomized study to evaluate efficacy and tolerability of enteric-coated mycophenolate sodium 1440 mg/day with tacrolimus reduced dose versus enteric-coated mycophenolate sodium 720 mg/day with tacrolimus standard dose, in maintenance, stable, adult, kidney transplant recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2012

At a glance

  • Drugs Mycophenolate sodium; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 02 Feb 2012 Primary endpoint 'Glomerular-filtration-rate' has been met.
    • 01 Feb 2012 Planned number of patients (98) added as reported in Clinical Nephrology.
    • 01 Feb 2012 Results published in the Clinical Nephrology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top